154 related articles for article (PubMed ID: 25317746)
1. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
[TBL] [Abstract][Full Text] [Related]
2. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
3. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
6. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
7. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
8. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
9. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
10. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Todd JR; Becker TM; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
[TBL] [Abstract][Full Text] [Related]
11. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
12. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
13. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
15. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
Smalley KS; Sondak VK; Weber JS
Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
[TBL] [Abstract][Full Text] [Related]
16. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
[No Abstract] [Full Text] [Related]
17. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
[TBL] [Abstract][Full Text] [Related]
18. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
19. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
[No Abstract] [Full Text] [Related]
20. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
